Morris A Phase 1-2 Study of HLD-0915 in People With Advanced Prostate Cancer A Phase 1b Study of Xaluritamig in People With Castration-Sensitive Prostate Cancer A Phase 1b/2 Study of Tinengotinib (TT-00420) Plus Standard Treatments in People With Advanced Prostate Cancer A Phase 2 Study of Ac-225 Rosopatamab Tetraxetan (CONVO1-Alpha) in People With Advanced Prostate Cancer A Phase 2 Study of Tarlatamab for People With Advanced Prostate Cancer A Phase 3 Study Comparing Lutetium Vipivotide Tetraxetan (AAA617, Pluvicto) With Observation in People with Prostate-Specific Membrane Antigen (PSMA)-Positive Oligometastatic Prostate Cancer A Phase 3 Study of Xaluritamig Versus Cabazitaxel or Second Androgen Receptor-Directed Therapy for People With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) with Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3) A Phase I Study of AMG 509 in Men with Advanced Prostate Cancer A Phase I Study of ORIC-944 to Treat Metastatic Prostate Cancer A Study of AZD0516 in People With Prostate Cancer A Study of AZD6621 in People With Prostate Cancer A Study of Stereotactic Body Radiotherapy (SBRT) and Pluvicto (177Lu-PSMA-617) in People With Prostate Cancer Testing different dosing schedules of the anti-cancer drug, Lutetium-177-PSMA (Pluvicto), and its effect on patients with advanced prostate cancer Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer
However, tumor cells can evade PCD through dysregulation of apoptotic signals, such as the activation of anti-apoptotic systems, leading to cancer recurrence
Dakic V, Minardi Nascimento J, Costa Sartore R, MacIel RDM, De Araujo DB, Ribeiro S, et al
McGregor et al., 2019
In both methods serial dilutions of a GSH standard solution were used to generate a standard curve, and the GSH concentration was normalized to the protein concentration of each well
FD appears to have some common inflammation pathways with some of these diseases including cytokine mediated inflammation via IL-1, mitochondrial dysfunction leading to ROS (105) and lysosomal dysfunction leading to NLRP3 activation (106)
